Michel Sadelain, MD, PhD

T-cell Based Therapeutics

Michel Sadelain, MD, PhD, is the founding director of the Columbia Institute for Cell Engineering and Therapy at Columbia University and a pioneer in CAR-T cell therapy. His work has made key contributions to the development of CD19 CAR therapy and T-cell engineering, advancing new cell-based approaches for treating human disease.

Ryan Ungaro, MD, MS

The INTERCEPT Consortium

Ryan Ungaro, MD, MS, is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the COMPASS-IBD Program. His research focuses on early IBD, disease prediction and prevention, early intervention, and precision medicine. He is a member of the steering committee for INTERCEPT; an international effort focused on identifying individuals in the earliest stages of Crohn's disease and advancing strategies to intercept disease before progression.

Steven St. Peter, MD

Co-founder & Managing Director
Vie Ventures

Steven St. Peter, MD, is the Founder and Managing Director of Vie Ventures, a next-generation biotech venture capital firm integrating traditional investing with disease-focused philanthropy. As both an investor and entrepreneur, he brings a unique perspective on innovation, company creation, and capital formation within biotech.